Emetogenic potential of single intravenous antineoplastic agents

High
Anthracycline/cyclophosphamide combination^* Carmustine Chlormethine (mechlorethamine) Cisplatin Cyclophosphamide ≥1500 mg/m² Dacarbazine Streptozocin
Moderate
Alemtuzumab Arsenic trioxide Azacitidine Bendamustine Busulfan Carboplatin^¶ Clofarabine Cyclophosphamide <1500 mg/m² Cytarabine >1000 mg/m² Cytarabine/daunorubicin liposomal Daunorubicin Dinutuximab beta Doxorubicin Epirubicin	Idarubicin Ifosfamide Irinotecan Irinotecan peg-liposomal Lurbinectedin Naxitamab Oxaliplatin Romidepsin Sacituzumab-govitecan^Δ Temozolomide^◊ Thiotepa^§ Trabectedin Trastuzumab-deruxtecan^Δ
Low
Aflibercept Amivantamab Axicabtagene-ciloleucel Belinostat Blinatumomab Bortezomib Brentuximab-vedotin Cabazitaxel Carfilzomib Catumaxomab Cetuximab Copanlisib Cytarabine ≤1000 mg/m² Decitabine Docetaxel Doxorubicin peg-liposomal Elotuzumab Enfortumab-vedotin Eribulin Etoposide 5-Fluorouracil Gemcitabine Gemtuzumab-ozogamicin Inotuzumab-ozogamicin Isatuximab	Ixabepilone Loncastuximab-tesirine Margetuximab Melphalan-flufenamide Methotrexate Mirvetuximab-soravtansine Mitomycin Mitoxantrone Moxetumomab-pasudotox Necitumumab Nelarabine Paclitaxel Paclitaxel nab-albumin Panitumumab Pemetrexed Pertuzumab Tafasitamab Tagraxofusp Teclistamab Temsirolimus Tisagenlecleucel Tisotumab-vedotin Topotecan Trastuzumab-emtansine Vinflunine
Minimal
Asparaginase^¥ Atezolizumab Avelumab Belantamab-mafodotin Bevacizumab Bleomycin Cemiplimab Cladribine (2-chlorodeoxyadenosine) Daratumumab Dostarlimab Durvalumab Emapalumab Fludarabine Ipilimumab Mosunetuzumab	Nivolumab Obinutuzumab Ofatumumab Pembrolizumab Pixantrone Polatuzumab-vedotin Pralatrexate Ramucirumab Rituximab Trastuzumab Tremelimumab Vinblastine Vincristine Vinorelbine

* The combination of an anthracycline and cyclophosphamide in patients with breast cancer is highly emetogenic.

¶ Emetic potential appears to be at the high end of the moderate category.

Δ Emetic potential appears to be at the high end of the moderate category, most closely resembling that of carboplatin.

◊ No direct evidence found for temozolomide IV; as all sources indicate a similar safety profile of oral temozolamide, the classification was based on oral temozolomide.

§ Classification refers to individual evidence from pediatric trials.

¥ Asparaginase erwinia chrysanthemi (crisantaspase) and asparaginase (calaspargase pegol).

From: Jordan K, Chan A, Gralla RJ, et al. Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents—updated MASCC/ESMO consensus recommendation. Support Care Cancer 2023; 32:53. Copyright © 2023 The Authors. Available at: https://link.springer.com/article/10.1007/s00520-023-08220-5 (Accessed on April 11, 2024). Reproduced under the terms of the Creative Commons Attribution License 4.0.

Graphic 144746 Version 1.0

UpToDate خرید پکیج

Emetogenic potential of single intravenous antineoplastic agents

خرید پکیج